|1.||Xu, Wenfang: 23 articles (08/2013 - 01/2005)|
|2.||Fang, Hao: 13 articles (06/2013 - 05/2007)|
|3.||Reinhold, Dirk: 11 articles (01/2012 - 01/2006)|
|4.||Bank, Ute: 10 articles (01/2012 - 01/2006)|
|5.||Ansorge, Siegfried: 10 articles (01/2012 - 01/2006)|
|6.||Lendeckel, Uwe: 10 articles (01/2010 - 12/2003)|
|7.||Corti, Angelo: 9 articles (12/2013 - 11/2003)|
|8.||Ponzoni, Mirco: 7 articles (08/2015 - 11/2003)|
|9.||Wang, Xuejian: 7 articles (10/2012 - 12/2008)|
|10.||Täger, Michael: 7 articles (01/2012 - 01/2006)|
02/01/2013 - "Aminopeptidase N (APN) inhibitors have been reported to be effective in treating of life threatening diseases including cancer. "
01/15/2004 - "We have shown previously that targeted delivery of TNF to aminopeptidase N (CD13), a marker of angiogenic vessels, improved the therapeutic index of this cytokine in tumor-bearing mice. "
01/20/2004 - "In present study, PsA was found to inhibit mammalian aminopeptidase N (APN) that plays a key role in tumor cell invasion and angiogenesis. "
12/01/2015 - "Aminopeptidase N (APN, also known as CD13) is involved in cellular processes of various types of tumors and a potential anti-cancer therapeutic target. "
07/01/2015 - "Aminopeptidase N (APN/CD13) is involved in tumor cell invasion and tumor angiogenesis and is considered a promising therapeutic target in the treatment of cancer. "
|2.||Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
12/15/2005 - "The aim of this study was to evaluate the clinical significance of circulating aminopeptidase N/CD13 protein detected by mAb MH8-11 in patients with non-small cell lung cancer (NSCLC). "
01/01/2015 - "Expression and clinical significance of aminopeptidase N/CD13 in non-small cell lung cancer."
11/01/2009 - "Stromal aminopeptidase N expression: correlation with angiogenesis in non-small-cell lung cancer."
07/01/2006 - "Clinical significance of aminopeptidase N in non-small cell lung cancer."
12/15/2005 - "Circulating aminopeptidase N/CD13 is an independent prognostic factor in patients with non-small cell lung cancer."
01/01/2010 - "Expression of CD13/aminopeptidase N in precursor B-cell leukemia: role in growth regulation of B cells."
04/28/2006 - "A mutation in aminopeptidase N (CD13) isolated from a patient suffering from leukemia leads to an arrest in the endoplasmic reticulum."
10/01/2004 - "Most of them had the morphological changes such as the leukemia cells' indent nucleus with a light stain region of perinucleus, basophilic cytoplasm, differentiation with maturation, megaloblastoid changes and nuclear-cytoplasm imbalance; the high expression of CD13 antigen; and the AML1/ETO fusion transcript in 23 cases examined by reverse transcription-polymerase chain reaction (RT-PCR) assay, including 6 cases with normal karyotype. "
09/01/1995 - "We have investigated the compartmentalization of aminopeptidase-N-like activity in various blood fractions obtained from patients with acute lymphoid (ALL) or myeloid (AML) leukemia. "
08/01/1990 - "Patients with CD34+ leukemia were more likely to have blasts expressing CD22, CD9, and CD13 antigens but were less likely to coexpress CD20. "
|4.||Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental)
06/01/1995 - "Because acute experimental autoimmune encephalomyelitis (EAE) is characterized by a transient and focal perturbation of the BBB, we have utilized the model of adoptive transfer EAE to correlate the expression of the pericytic aminopeptidase N (pAP N) with the acute functional state of the BBB. "
06/01/1995 - "Changes in the expression pattern of blood-brain barrier-associated pericytic aminopeptidase N (pAP N) in the course of acute experimental autoimmune encephalomyelitis."
03/01/2011 - "PETIR-001, a dual inhibitor of dipeptidyl peptidase IV (DP IV) and aminopeptidase N (APN), ameliorates experimental autoimmune encephalomyelitis in SJL/J mice."
01/01/2009 - "Moreover, these inhibitors are capable of attenuating the severity of autoimmune diseases, such as experimental autoimmune encephalomyelitis, the animal model of multiple sclerosis, and experimental arthritis, a model of human rheumatoid arthritis, in vivo, particularly in combination with inhibitors of aminopeptidase N (APN, CD13) enzymatic activity. "
|1.||Dipeptidyl Peptidase 4 (Dipeptidyl Peptidase IV)
|4.||Peptide Hydrolases (Proteases)
|5.||Opioid Peptides (Opioid Peptide)
|6.||Transforming Growth Factor beta1 (TGF beta 1)
|8.||Protease Inhibitors (Protease Inhibitor)
|10.||Neprilysin (Neutral Endopeptidase)
|2.||Heterologous Transplantation (Xenotransplantation)